Stock Watch: Why Have All The Buyouts Gone?

Due Diligence Tempers Pharma's Drive To Refresh Pipeline Through M&A

Clinical trial results that readily excite stock market investors are subject to more stringent analysis by big pharma deal-hunters, despite their urgent need for pipeline renewal.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

At the end of May 2024, the NASDAQ Biotech Index (NBI) fell into negative territory both in the year to date and compared with the previous 12 months. This was despite the imperative on big pharma companies to refresh their pipelines through the acquisition of smaller biotech companies. This imperative is driven by the pressure of Medicare price renegotiation, the biosimilar patent cliff and the failure of big pharma’s innovative products for rare and orphan patient populations to replace the sales of their older blockbusters for bigger indications. In the past, pipeline expansion would have been achieved by two means: mergers of big pharma and the acquisition of smaller biotechs. With the competition authorities breathing down necks to dissuade transactions that achieve the former, we should already be knee-deep in a golden age of biotech acquisitions. In the three hot areas of obesity, radiopharmaceuticals and antibody-drug conjugates, this remains true. However, a therapeutically wider renaissance of biotech acquisitions is probably being prevented by good holistic due diligence, and some valuation sensitivity.

In the years before Pfizer Inc.’s* 2016 acquisition of Medivation, Inc. for $14bn, largely for its androgen receptor inhibitor Xtandi (enzalutamide) for prostate cancer, Medivation’s prime focus was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Stock Watch

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By 

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By 

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By 

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By 

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

More from Business

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By 

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.